Palvella Therapeutics (NASDAQ:PVLA) Releases Earnings Results, Beats Estimates By $0.08 EPS

Palvella Therapeutics (NASDAQ:PVLA) announced its quarterly earnings results on Thursday. The company reported ($1.70) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.08, FiscalAI reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• Positive sentiment: The FDA accepted Palvella’s QTORIN rapamycin NDA for microcystic lymphatic malformations and granted Priority Review, setting a February 28, 2027 PDUFA date. If approved, it would be the first FDA-approved treatment for the condition.
• Positive sentiment: Management cited physician research showing more than 70% of surveyed doctors expect to prescribe QTORIN rapamycin within three months of approval. The company estimates more than 30,000 diagnosed U.S. patients and says the opportunity could exceed $1 billion in peak annual U.S. sales; these are company estimates, not established results.
• Positive sentiment: Palvella said it is preparing a roughly 70-person commercial and medical team for a potential launch, including about 40 frontline sales representatives. Payer discussions have been constructive, though coverage and access remain to be established.
• Positive sentiment: The company plans to start a Phase III study of QTORIN rapamycin for cutaneous venous malformations this quarter and expects Phase II results for angiokeratomas in the second half of 2027. It also reported continued development progress for its DSAP candidate, extending its pipeline beyond the lead program.
• Negative sentiment: Palvella ended Q3 with $236.7 million in cash and said it expects funding to last deep into a potential launch, but anticipates its largest investment to date in Q4 as hiring and pre-commercial spending increase. Management cautioned that early revenue may lag demand while payer coverage, treatment-center workflows, and patient access processes are established, and it will not provide specific 2027 revenue guidance.

Palvella Therapeutics Stock Performance

PVLA stock traded up $19.07 during trading on Friday, hitting $175.92. 502,014 shares of the company’s stock traded hands, compared to its average volume of 237,190. The business has a fifty day simple moving average of $142.54 and a two-hundred day simple moving average of $128.12. Palvella Therapeutics has a 1 year low of $72.22 and a 1 year high of $176.94.

Insider Buying and Selling

In other news, Director George Jenkins sold 7,174 shares of the firm’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total value of $935,202.64. Following the sale, the director directly owned 139,790 shares in the company, valued at approximately $18,223,024.40. This trade represents a 4.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total value of $537,313.54. Following the transaction, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This represents a 66.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,056 shares of company stock worth $8,756,946 in the last three months. 17.20% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on PVLA. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. William Blair began coverage on shares of Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Oppenheimer lifted their price target on Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a research report on Friday. Chardan Capital reissued a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, October 28th. Finally, Canaccord Genuity Group set a $232.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $213.00.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.